ResMed Inc (LTS:0KW4)
$ 248.625 -8.5249 (-3.32%) Market Cap: 36.23 Bil Enterprise Value: 36.66 Bil PE Ratio: 32.69 PB Ratio: 6.97 GF Score: 96/100

Q1 2025 ResMed Inc Earnings Call Transcript

Oct 24, 2024 / 08:30PM GMT
Release Date Price: $241.88 (+2.07%)

Key Points

Positve
  • ResMed Inc (RMD) reported a strong quarter with an 11% revenue growth, driven by demand for sleep health and breathing health medical devices.
  • The company achieved a 27% growth in operating profit and a 34% increase in earnings per share, showcasing strong financial performance.
  • ResMed Inc (RMD) is expanding the availability of its AirSense 11 platform worldwide, which is expected to drive ongoing momentum.
  • The masks and accessories segment saw an 11% year-over-year growth, supported by new patient activations and ReSupply programs.
  • The company is leveraging macro trends such as consumer wearables and GLP-1 medications, which are expected to provide significant tailwinds for the business.
Negative
  • ResMed Inc (RMD) faces potential headwinds from the Middle East conflict and congestion in Asian ports, which could impact freight costs.
  • The company is experiencing increased air and sea freight costs, which are expected to continue affecting gross margins throughout fiscal year 2025.
  • There is a risk of a more price-sensitive environment if competitors like Philips return to the market, potentially impacting market share.
  • ResMed Inc (RMD) is dealing with inventory build-up as it balances freight costs, which could affect cash flow in the short term.
  • The company is navigating a complex competitive landscape in Europe and Asia, requiring continuous innovation and strategic positioning.
Operator

Hello, and welcome to the Q1 fiscal year 2025 ResMed Earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note this conference call is being recorded.

I'll now turn the call over to Amy Wakeham, Chief Investor Relations Officer. Amy, you may begin.

Amy Wakeham
Resmed Inc - Chief Investor Relations Officer

Great. Thank you, Kevin. Hi, everyone, and welcome to ResMed's first quarter fiscal year 2025 earnings call. As Kevin said, we are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings press release and presentation are both available online now.

During today's call, we will discuss several non-GAAP measures that we believe provide helpful information for investors. This information is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot